Geron Appoints Dr. Joseph Eid to Boost Blood Cancer Research and Development Efforts

Geron Corporation Strengthens Leadership to Advance Blood Cancer Treatments

Geron Corporation, a biopharmaceutical company dedicated to transforming the treatment landscape for blood cancers, announces a significant leadership change aimed at enhancing its research and development capabilities. Effective November 11, 2024, Dr. Joseph Eid takes on the role of Executive Vice President of Research and Development. In this pivotal position, Dr. Eid will oversee Geron’s R&D organization, which encompasses medical, clinical, and safety/pharmacovigilance teams. His appointment is poised to drive innovative strategies that support the commercial success of RYTELO™ (imetelstat), Geron’s first-in-class telomerase inhibitor, which has recently gained FDA approval for treating specific adult patients with lower-risk myelodysplastic syndromes (LR-MDS).

Dr. Eid brings over two decades of experience in the biopharmaceutical sector, with a robust background in medical affairs, clinical development, and drug life-cycle management. His career highlights include significant leadership roles at companies like Dragonfly Therapeutics and Luzsana Bio, as well as a formative tenure at Roche, where he started in clinical oncology drug development. At Merck, he played a crucial role in developing the KEYTRUDA® program and establishing the Oncology Global Medical Affairs organization. Geron’s CEO, Dr. John A. Scarlett, emphasizes that Dr. Eid’s extensive experience in hematology and oncology will facilitate greater collaboration within the company, ultimately improving the potential for RYTELO to make a meaningful impact in the treatment of blood cancers.

The strategic appointment of Dr. Eid comes at a critical time for Geron as it advances its pivotal Phase 3 clinical trial of imetelstat for patients with JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). Geron is also exploring the application of imetelstat in other hematologic malignancies, which underscores the company’s commitment to addressing unmet medical needs within this challenging therapeutic area. The mechanism of action for imetelstat, centered around inhibiting telomerase activity, positions it as a potentially transformative treatment option that could lead to reduced cell proliferation and death of malignant cells in the bone marrow.

In tandem with these developments, Geron’s management team is set to participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York City on November 18, 2024. This event will provide an opportunity for Geron to engage with the investment community and share insights about its ongoing initiatives, particularly in relation to RYTELO and its research pursuits. For those interested in following Geron’s progress, detailed information can be found on their website and LinkedIn page. The company’s proactive approach in leadership enhancement and community engagement reflects its unwavering mission to improve outcomes for patients battling blood cancers.